HER2阳性型乳腺癌脑转移的研究进展  

Review on Brain Metastases in HER2-positive Breast Cancer Patients

作　　者：周霞[1] 杜向慧[1] 裘国勤[1] 

机构地区：[1]浙江省肿瘤医院胸部肿瘤放射治疗科,杭州310022

出　　处：《肿瘤防治研究》2014年第6期680-685,共6页Cancer Research on Prevention and Treatment

基　　金：浙江省医药卫生科技计划资助项目(2011KYB024);浙江省中医药科技计划资助项目(2011ZA013)

摘　　要：近年来曲妥珠单抗的广泛应用大大提高了HER2(人表皮生长因子受体2)过度表达乳腺癌患者的生存率,在全身性控制率提高和生存期延长的同时,脑转移瘤的发病率也有所增加。脑转移是造成HER2阳性型乳腺癌晚期患者死亡的一项越来越重要的具有临床挑战性的因素——常常是在颅外疾病控制良好的情况下。本文对HER2阳性型乳腺癌脑转移的早期检测和预防的价值,靶向治疗的进展及新靶向药物的开发情况加以总结。The widespread use of trastuzumab in recent years has led to a significant improvement in the survival of breast cancer patients with overexpressed human epidermal growth factor receptor-2(HER2-positive). However with improved systemic control and prolonged survival, the incidence of brain metastasis has increased. Brain metastasis, often in the setting of well-controlled extracranial disease, is proved to be an increasingly important and clinically challenging cause of morbidity and mortality in HER2-positive breast cancer patients. In this review, we will discuss the targeted therapies of HER2-positive brain metastasis and summarize information about ongoing clinical trials of novel therapies as well as emerging strategies for early detection and prevention.

关 键 词：人表皮生长因子受体2 乳腺癌 脑转移 血脑屏障 曲妥珠单抗 拉帕替尼 

分 类 号：R73[医药卫生—肿瘤]